Africa reports nearly 20 million measles deaths averted since 2000

WHO and Gavi say measles vaccinations have averted nearly 20 million deaths in Africa since 2000 and more than 500 million children were protected through routine immunisation; the analysis also reports that the region remains off track to meet 2030 coverage targets.

A new analysis from the World Health Organization and Gavi finds that measles vaccinations have averted nearly 20 million deaths in Africa since 2000 and that routine programmes have protected more than 500 million children. The study covers 2000–2024 and documents expanded immunisation, including wider use of a second measles dose and supplemental campaigns. It also notes uneven progress across countries and that the region is not on track to meet the 2030 Immunization Agenda coverage goals. WHO and Gavi reported ongoing efforts to widen coverage and introduce new vaccines. Key findings: - Nearly 20 million measles deaths averted in Africa between 2000 and 2024. - More than 500 million children protected through routine immunisation during the same period. - Forty-four countries introduced a second measles dose; coverage rose from 5% to 55%, and supplemental campaigns delivered 622 million vaccinations. - Measles deaths in the region have been halved and overall cases fell by about 40%. - Cabo Verde, Mauritius and the Seychelles were verified in 2025 as having eliminated measles and rubella; nine countries reported consistently low measles incidence in 2023–24. - Routine schedules now protect against 13 vaccine-preventable diseases (up from eight in 2000); the malaria vaccine has been introduced in 25 countries, and vaccinations saved an estimated 1.9 million lives in 2024 (about 42% attributed to measles vaccination). Summary: The analysis highlights large, measurable gains in vaccination coverage and lives saved while also showing uneven progress and missed targets for 2030. WHO and Gavi call for continued investment and political commitment and say they are working with governments to expand coverage and accelerate introductions of new vaccines such as malaria and HPV. The path to reach the 90% coverage goal at key life stages remains a work in progress.